{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:23:00Z","timestamp":1791390180980,"version":"4.3.3"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cytarabine is a nucleoside analog used in chemotherapy regimens for the treatment of multiple hematologic malignancies. One of the known adverse effects of cytarabine, particularly in patients receiving high-dose cytarabine (HDAC), is drug-induced fever. Multiple studies have demonstrated an increased risk of viridans group streptococcal bacteremia in patients who have received HDAC. For this reason, our institution and several other institutions across the country routinely include vancomycin as empiric coverage for patients who develop fever during HDAC, due to concern for resistance to cephalosporin monotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>Patient demographic, diagnosis, treatment, and outcome information was collected by electronic chart review for each HDAC infusion from 2007 to August 2018 at the University of Iowa Stead Family Children\u2019s Hospital. If fever was documented during or within 24 hours of HDAC, additional information was collected regarding patient outcome and diagnostic testing.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 208 HDAC administrations documented, patients developed fevers during the course on 82 occasions (39.4%). A median of 3 blood cultures per febrile period were obtained from time of fever onset during HDAC administration through &gt;24 hours afebrile. One blood culture was positive for an oral flora organism determined by the microbiology lab report to be a likely contaminant. There were no other positive blood cultures in non-neutropenic or neutropenic patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Fever due to HDAC is relatively common but appears to frequently lack association with bacteremia during the time of HDAC administration. Broad-spectrum empiric antibiotic regimens including vancomycin may be unnecessary for these patients, particularly before they become neutropenic.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000002073","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T23:57:55Z","timestamp":1613951875000},"page":"e1010-e1014","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Evaluation of Empiric Vancomycin for Fevers During High-dose Cytarabine Administration"],"prefix":"10.1097","volume":"43","author":[{"given":"Alex","family":"Hoover","sequence":"first","affiliation":[{"name":"Stead Family Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica A.O.","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, University of Iowa Stead Family Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawyer","family":"Wiese","sequence":"additional","affiliation":[{"name":"Department of Health and Human Physiology, University of Iowa, Iowa City, IA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunkumar","family":"Modi","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, University of Iowa Stead Family Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/mpo.1230","article-title":"Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children","volume":"37","author":"Ek","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.mph.0000173176.33271.8f","article-title":"Ara-C fever and infections after high-dose ara-C treatment in pediatric lymphoid malignancies","volume":"27","author":"Ek","year":"2005","journal-title":"J Pediatr Hematol Oncol"},{"key":"R3-20250804","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00001813-200501000-00008","article-title":"Cytarabine-induced fever complicating the clinical course of leukemia","volume":"16","author":"Gonen","year":"2005","journal-title":"Anticancer Drugs"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/mpo.2950090309","article-title":"The cytosine arabinoside (Ara-C) syndrome","volume":"9","author":"Castleberry","year":"1981","journal-title":"Med Pediatr Oncol"},{"key":"R5-20250804","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0959-8049(03)00272-7","article-title":"Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors","volume":"39","author":"Paganini","year":"2003","journal-title":"Eur J Cancer"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1592\/phco.19.16.1315.30867","article-title":"Evaluation of empiric vancomycin therapy in children with fever and neutropenia","volume":"19","author":"Adcock","year":"1999","journal-title":"Pharmacotherapy"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7883\/yoken.JJID.2018.074","article-title":"Streptococcus mitis\/oralis causing blood stream infections in pediatric patients","volume":"72","author":"Basaranoglu","year":"2019","journal-title":"Jpn J Infect Dis"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s15010-013-0470-7","article-title":"Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia","volume":"41","author":"Han","year":"2013","journal-title":"Infection"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/jac\/47.1.87","article-title":"High rates of resistance to cephalosporins among viridans-group streptococci causing bacteraemia in neutropenic cancer patients","volume":"47","author":"Marron","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jpeds.2010.08.019","article-title":"Incidence and risk factors influencing the development of vancomycin nephrotoxicity in children","volume":"158","author":"McKamy","year":"2011","journal-title":"J Pediatr"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"e0202439","DOI":"10.1371\/journal.pone.0202439","article-title":"Vancomycin associated acute kidney injury in pediatric patients","volume":"13","author":"Moffett","year":"2018","journal-title":"PLoS One"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1200\/JCO.2016.71.7017","article-title":"Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients","volume":"35","author":"Lehrnbecher","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002073","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T20:09:25Z","timestamp":1754338165000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000002073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000002073","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"2020-06-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}